| Business Summary | | Abgenix,
Inc.
is
a
biopharmaceutical
company
that
develops
and
intends
to
commercialize
antibody
therapeutic
products
for
the
treatment
of
a
variety
of
disease
conditions,
including
transplant-related
diseases,
inflammatory
and
autoimmune
disorders,
cardiovascular
disease,
infectious
diseases
and
cancer.
The
Company
has
three
antibody
product
candidates
that
are
currently
in
clinical
trials.
These
are
ABX-IL8,
ABX-EGF,
and
ABX-CBL.
ABX-IL8
is
the
Company's
fully
human
antibody
candidate
for
the
treatment
of
psoriasis
and
rheumatoid
arthritis.
ABX-EGF
is
the
Company's
fully
human
antibody
candidate
for
the
treatment
of
a
variety
of
cancers.
ABX-CBL
is
an
in-licensed
mouse
antibody,
for
the
treatment
of
a
transplant-related
disease
known
as
graft
versus
host
disease. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Abgenix,
Inc.
develops
and
intends
to
commercialize
antibody
therapeutic
products
for
the
treatment
of
a
variety
of
disease
conditions.
For
the
six
months
ended
6/30/01,
revenues
rose
64%
to
$30.5
million.
Net
loss
totaled
$22.4
million,
up
from
$5.8
million.
Revenues
reflect
a
$9
million
proprietary
product
development
fee
under
agreements.
Higher
loss
reflects
an
increase
in
personnel
expenses
and
higher
amortization
of
goodwill
charges. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| R. Scott Greer, 42 Chairman,
CEO | $616K | $27.4M | Raymond Withy, Ph.D., 45 Pres,
COO | 332K | 15.0M | Kurt Leutzinger, 49 CFO | 337K | 3.0M | C. Geoffrey Davis, Ph.D., 49 CSO | 327K | -- | Susan Thorner, 52 VP,
Gen. Counsel, Sec. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|